OraSure Technologies reported Q1 2026 results after the close on May 6 — a small revenue beat against an EPS miss — and the print lands at a moment when the stock's own leadership has been among its most active buyers.
CEO Carrie Eglinton Manner and CFO Ken McGrath together purchased roughly 108,600 shares in two coordinated buying windows in March, at prices around $2.93 to $3.00 per share. That cluster of insider buying, totalling over $320,000 in combined value, represents the clearest signal of confidence from within the building. The net 90-day insider position is positive — around 332,000 shares bought on balance — making this one of the more constructive insider setups for a small-cap health-care name right now.
The Q1 print itself was mixed. Revenue of $27.9 million beat the $27.7 million estimate by a narrow margin. Adjusted EPS of -$0.24 missed the -$0.23 consensus. The forward guide — Q2 sales of $27 million to $30 million against a $29.1 million estimate — straddles the midpoint in a way that leaves room for interpretation. The stock closed at $3.00 on May 5, barely changed on the week and down about 2.6% over the past month. Earnings history is worth noting: the prior two results events each produced single-day moves of around 9-12%, both to the upside.
Short positioning is a secondary story here, not the primary one. Short interest runs at 4.4% of the free float — material enough to watch but not extreme. What is notable is the clear directional retreat: short positions fell roughly 15% over the past 30 days, from a peak above 3.7 million shares in late March down to 3.16 million. Borrowing costs are low and falling fast, down nearly 30% on the week to 0.59% annualised, the cheapest level in the tracked period. Availability in the lending market is ample — there is no squeeze dynamic building here. The ORTEX short score of 48.3 sits squarely at the midpoint of the range, consistent with a fading short thesis rather than an escalating one.
Analyst coverage is thin and the most recent actionable data is dated. Stephens lowered its target to $3.00 from $3.50 in November 2025, maintaining Equal-Weight. Evercore ISI held at $3.00 with an In-Line rating in the same period. The current stock price matches the consensus target exactly, leaving no formal upside embedded in the Street's published numbers — though those numbers are now more than six months old. The EPS surprise factor score ranks in the 90th percentile, suggesting the company has a track record of clearing the bar even if the margin is slim.
The institutional register shows BlackRock adding 128,686 shares as of April 30, now at 9.3% of shares outstanding. Altai Capital trimmed by 127,000 shares to 5.2% in mid-April. Broadfin Capital entered as a new holder with 1.8 million shares as of year-end, the largest net addition in the recent filing cycle. That mix of a long-only active manager building and a healthcare specialist trimming captures the tension on the stock fairly well.
The next scheduled earnings call is June 3. How management frames the Q2 guidance range — and whether the revenue beat in Q1 is enough to re-anchor the Street's estimates — is what traders will be watching.
See the live data behind this article on ORTEX.
Open OSUR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
